Etienna Bio Announces Formation of Scientific Advisory Board with UMass Chan Leaders

Silvia Corvera, MD, and Michael Czech, PhD, join SAB to advance autologous regenerative cell platform

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Etienna Bio, Inc., a regenerative biotechnology company, has announced the formation of its Scientific Advisory Board (SAB) with the appointment of two renowned leaders in cell biology and metabolic science from UMass Chan Medical School: Silvia Corvera, MD, and Michael P. Czech, PhD. The SAB will provide strategic guidance as Etienna Bio advances its proprietary autologous adipose-derived cell and scaffold platform across multiple aesthetic and reconstructive applications.

Why it matters

The formation of this high-caliber SAB marks a significant milestone for Etienna Bio as it seeks to translate its science into durable, clinically meaningful outcomes and build a category-defining regenerative platform. Drs. Corvera and Czech are globally respected authorities whose work has shaped modern understanding of adipose biology, and their guidance will be instrumental in Etienna Bio's development efforts.

The details

Etienna Bio's proprietary platform combines autologous adipose-derived cells with a thermosensitive scaffold, designed to improve tissue persistence, vascularization, and functional integration. The company is developing this technology across multiple high-growth aesthetic and reconstructive markets, leveraging a single patient micro harvest to address diverse needs.

  • Etienna Bio announced the formation of its Scientific Advisory Board on February 11, 2026.

The players

Etienna Bio, Inc.

A regenerative biotechnology company developing an autologous adipose-derived cell platform for aesthetic and reconstructive applications.

Silvia Corvera, MD

A distinguished physician-scientist and professor at UMass Chan, widely recognized for her pioneering work in cellular trafficking, endosomal biology, and adipose tissue function.

Michael P. Czech, PhD

A world-renowned biochemist and professor emeritus at UMass Chan, best known for foundational discoveries in insulin signaling, adipocyte biology, and metabolic regulation.

Janet DeLeon

The Chief Executive Officer of Etienna Bio.

UMass Chan Medical School

One of five campuses of the University of Massachusetts system, comprising the T.H. Chan School of Medicine, the Morningside Graduate School of Biomedical Sciences, the Tan Chingfen Graduate School of Nursing, and other divisions.

Got photos? Submit your photos here. ›

What they’re saying

“Establishing a Scientific Advisory Board of this caliber marks a major milestone for Etienna Bio. Dr. Corvera and Dr. Czech are globally respected authorities whose work has shaped modern understanding of adipose biology. Their guidance will be instrumental as we translate our science into durable, clinically meaningful outcomes and build a category-defining regenerative platform.”

— Janet DeLeon, Chief Executive Officer, Etienna Bio (Globe Newswire)

“This is a particularly exciting opportunity to help guide a technology that leverages the intrinsic biology of adipose-derived cells in a clinically elegant way. Etienna Bio's approach aligns closely with emerging scientific understanding of tissue regeneration and cellular integration.”

— Silvia Corvera, MD, Endowed Chair in Diabetes Research and Professor of Molecular Medicine, UMass Chan (Globe Newswire)

“Etienna Bio is advancing a thoughtful, biology-driven platform with broad potential. I look forward to contributing scientific perspective as the company moves toward clinical and commercial translation.”

— Michael P. Czech, PhD, Isadore and Fannie Foxman Chair of Medical Research and Professor Emeritus of Molecular Medicine, UMass Chan (Globe Newswire)

What’s next

The SAB will support Etienna Bio's scientific strategy, preclinical and translational development, and regulatory engagement as the company prepares for FDA interactions and continued platform expansion.

The takeaway

The formation of Etienna Bio's Scientific Advisory Board with renowned experts from UMass Chan Medical School underscores the company's commitment to advancing a clinically meaningful, biology-driven regenerative platform that leverages the intrinsic properties of adipose-derived cells.